
Nanexa Investor Relations Material
Latest events

Q1 2025
Nanexa

Q1 2025
6 May, 2025

Q4 2024
19 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nanexa
Access all reports
Nanexa AB focuses on developing nanoparticle technology for drug delivery. The company utilizes their proprietary NxCore platform to transform drugs from conventional to nanomedicines. Their lead product candidate is Nanoxel, a nanomedicine that targets oral mucositis, a common and exceptionally debilitating side effect in cancer patients receiving chemotherapy and radiation therapies; and angina pectoris and heart failure caused by atherosclerosis, a build-up of plaque in the blood vessels. The company intends to transform new products into nanomedicines or develop completely new nanomedicines.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
NANEXA
Country
🇸🇪 Sweden